Anaplastic Lymphoma Kinase Inhibitors for the Treatment of ALK-Positive Cancers

被引：13
|
作者：
Kinoshita, Kazutomo [1 ]
Oikawa, Nobuhiro [1 ]
Tsukuda, Takuo [1 ]
机构：
[1] Chugai Pharmaceut Co Ltd, Div Res, Kamakura, Kanagawa, Japan
来源：
ANNUAL REPORTS IN MEDICINAL CHEMISTRY, VOL 47 | 2012年 / 47卷
关键词：
CELL LUNG-CANCER; EXPERIMENTAL-MODELS; ANTITUMOR-ACTIVITY; RESISTANCE; FUSION; POTENT; IDENTIFICATION; CRIZOTINIB; MUTATIONS; PROTEINS;
D O I：
10.1016/B978-0-12-396492-2.00019-9
中图分类号：
R914 [药物化学];
学科分类号：
100701 ;
摘要：
引用
收藏
页码：281 / 293
页数：13
相关论文
共 50 条
  • [1] Anaplastic lymphoma kinase (ALK) inhibitors in the treatment of ALK-driven lung cancers
    Roskoski, Robert, Jr.
    PHARMACOLOGICAL RESEARCH, 2017, 117 : 343 - 356
  • [2] Anaplastic large cell lymphoma, ALK-positive
    Ferreri, Andres J. M.
    Govi, Silvia
    Pileri, Stefano A.
    Savage, Kerry J.
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2012, 83 (02) : 293 - 302
  • [3] Efficacy and Safety of Anaplastic Lymphoma Kinase (ALK) Tyrosine Kinase Inhibitors in ALK-Positive Non-Small Cell Lung Cancer
    Imase, R.
    Endo, S.
    Sasahara, Y.
    Shinmura, T.
    Ozawa, T.
    Majima, H.
    Hara, T.
    Shimada, H.
    Yamauchi, S.
    Sakakibara, Y.
    Kobayashi, A.
    Yamazaki, K.
    Jin, Y.
    Yamanaka, K.
    Matsubara, O.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S1953 - S1953
  • [4] Systematic Review and Network Meta-Analysis of Anaplastic Lymphoma Kinase (ALK) Inhibitors for Treatment-Naive ALK-Positive Lung Cancer
    Chuang, Cheng-Hao
    Chen, Hsiao-Ling
    Chang, Hsiu-Mei
    Tsai, Yu-Chen
    Wu, Kuan-Li
    Chen, I-Hua
    Chen, Kung-Chao
    Lee, Jui-Ying
    Chang, Yong-Chieh
    Chen, Chin-Ling
    Tu, Yu-Kang
    Hung, Jen-Yu
    Yang, Chih-Jen
    Chong, Inn-Wen
    CANCERS, 2021, 13 (08)
  • [5] A new variant anaplastic lymphoma kinase (ALK)-fusion protein (ATIC-ALK) in a case of ALK-positive anaplastic large cell lymphoma
    Trinei, M
    Lanfrancone, L
    Campo, E
    Pulford, K
    Mason, DY
    Pelicci, PG
    Falini, B
    CANCER RESEARCH, 2000, 60 (04) : 793 - 798
  • [6] Treatment-free remission after discontinuation of ALK tyrosine kinase inhibitors (TKIs) in patients with ALK-positive anaplastic large cell lymphoma (ALCL)
    Kim, Jinyong
    Kim, Soyeon
    Kim, Tae Min
    Youk, Jeonghwan
    Kim, Miso
    Keam, Bhumsuk
    Kim, Dong-Wan
    Heo, Dae Seog
    CANCER RESEARCH, 2023, 83 (07)
  • [7] Immune response to ALK in ALK-positive anaplastic large cell lymphoma
    Woessmann, W.
    BRITISH JOURNAL OF HAEMATOLOGY, 2015, 171 : 23 - 24
  • [8] Alectinib, an Anaplastic Lymphoma Kinase Inhibitor, Abolishes ALK Activity and Growth in ALK-Positive Neuroblastoma Cells
    Alam, Muhammad Wasi
    Borenas, Marcus
    Lind, Dan E.
    Cervantes-Madrid, Diana
    Umapathy, Ganesh
    Palmer, Ruth H.
    Hallberg, Bengt
    FRONTIERS IN ONCOLOGY, 2019, 9
  • [9] An Anaplastic Lymphoma Kinase (ALK) Immunohistochemical Pitfall: ALK-positive Histiocytosis versus Angiomatoid Fibrous Histiocytoma
    Chang, J.
    Diaz-Perez, J.
    Smith, S. C.
    AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 2024, 162 : S10 - S10
  • [10] Anaplastic lymphoma kinase (ALK) inhibitors for cancer treatment.
    Lee, Kvvangho
    Kim, Hyoung Rae
    Cho, Sung Yun
    Jung, Hee Jung
    Ha, Jae D.
    Yun, Chang-Soo
    Kim, Pilho
    Park, Chi Hoon
    Lee, Chong Ock
    MOLECULAR CANCER THERAPEUTICS, 2013, 12 (11)
12345